Latest Tyrosine kinase inhibitors Stories
EAST HANOVER, N.J., Dec.
NEW YORK, Dec. 3, 2010 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients.
BURLINGTON, Mass., Dec.
A new finding out in the December 1st issue of Genes & Development offers insight into a new treatment avenue for two painful inflammatory diseases: Crohn's Disease and sarcoidosis.
SINGAPORE, Nov. 22, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial.
Results from Phase II biomarker analysis of erlotinib in combination with sorafenib presented at Molecular Targets in Cancer Therapeutic meeting in Berlin, Germany. Broomfield, CO (Vocus) November 19, 2010 Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer (NSCLC) were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in...
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
Scientists believe they may have found a new target for treating triple negative breast cancer â€“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.
BROOMFIELD, Colo., Nov. 10, 2010 /PRNewswire/ -- Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, lead by existing investors.
BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc.
- Emitting flashes of light; glittering.